Industry Journal Feature | MiaoLingBio: 10+ Years of Expertise in Gene Vectors, Building a Leading I

In June 2026, We・BIO Bio Review, a journal published by the Wuhan East Lake High-Tech Development Zone Biopharmaceutical Industry Association, featured Wuhan MiaoLing Bio Technology Co., Ltd. in its cover-story series. The publication interviewed Yin Chu, Founder and General Manager of MiaoLingBio, providing an in-depth look at the company's more than decade-long development in Optics Valley BioCity, its focus on gene vector research and development, proprietary core technologies, and its efforts to support life science research and gene therapy drug development across China.

Cover of the June 2026 issue of《 We・BIO Bio Review》

1. Addressing a Critical Research Need: Building a Leading In-Stock Plasmid Resource Library in China

From basic gene function research to gene therapy drug development, plasmids are fundamental tools for a wide range of genetic engineering and molecular biology applications. In the past, researchers often spent one to two weeks constructing vectors themselves. Manual plasmid preparation could also result in insufficient purity, elevated endotoxin levels, and batch-to-batch variability, significantly slowing research progress.

MiaoLingPlasmid business portfolio

In-stock plasmid product boxes

With the rapid growth of the gene therapy industry, China's first gene therapy drug for hemophilia B has successfully received regulatory approval and entered the market. The viral vectors used as critical materials in the development of these therapies rely on plasmid DNA as an essential starting material.

As an upstream research tool provider, MiaoLingBio continues to provide standardized plasmid resources to support early-stage gene therapy drug development. The company has also initiated an expansion plan for its in-stock plasmid maxiprep library, with the goal of increasing production capacity for its 100,000-plasmid library by tenfold and further accelerating gene research and innovation worldwide.

2. Proprietary Magnetic Bead-Based Purification Technology Addresses Key Challenges in Plasmid Preparation

Plasmids are propagated in E. coli, and traditional manual plasmid extraction relies heavily on hands-on processing. This approach can be labor-intensive and makes it more difficult to achieve consistent control over impurities and endotoxin levels.

Endotoxin is a lipopolysaccharide component associated with the outer membrane of Gram-negative bacteria such as E. coli. If it is not adequately removed during plasmid purification, residual endotoxin can cause cytotoxic effects, reduce transfection efficiency, and interfere with downstream cell and animal experiments.

To address these common industry challenges, MiaoLingBio's R&D team spent two years developing proprietary magnetic bead-based purification reagents and compatible automated equipment. This resulted in a standardized domestic plasmid purification production line with several key improvements:

1. Significantly Higher Processing Efficiency

The automated equipment increased daily plasmid processing capacity from 24 mg to 240 mg, representing an approximately 10-fold improvement in overall process efficiency.

2. High and Consistent Quality Standards

Endotoxin levels in the purified plasmid products can be consistently controlled at ≤0.1 EU/μg. The resulting DNA is suitable for demanding applications such as mammalian cell transfection and viral vector production, including lentiviral and AAV packaging workflows.

3. Lower Research Costs

Proprietary supporting reagents reduce reliance on imported purification kits, helping research teams lower consumable costs. At the same time, automated workflows replace repetitive manual operations, substantially reducing hands-on labor and shortening the time required for process optimization and repeated experimental work.

This proprietary magnetic bead-based purification technology also provides a key technical foundation for MiaoLingBio's in-stock plasmid products, supporting high purity, a high proportion of supercoiled DNA, and consistent batch-to-batch quality.

3. Full-Chain Business Development Across Research and Agricultural Biotechnology

Building on its established capabilities in vector development and large-scale plasmid production, MiaoLingBio has developed a diversified business portfolio supporting both life science research and agricultural biotechnology.

1. End-to-End Services for Life Science Research

MiaoLingBio operates approximately 4,000 m² of standardized molecular biology laboratory facilities, along with an independent P2-level clean laboratory dedicated to viral operations. The company provides a comprehensive range of services, including in-stock plasmid supply, customized vector construction, milligram- to gram-scale plasmid preparation, and lentiviral/AAV packaging.

MiaoLingBio's products are shipped to countries around the world, including the United States, Japan, India, Russia, Canada, and Vietnam. To date, the company has served more than 6,000 universities, research institutes, and biotechnology and pharmaceutical companies across China, with more than 120,000 plasmid products delivered. Multiple plasmid vectors from the platform have been cited in thousands of academic publications in China and internationally.

2. Applying Biotechnology to Agricultural Breeding

MiaoLingBio has also extended its plasmid and biotechnology expertise into ecological agriculture. The company operates a 600-mu ecological orchard in Ezhou, where plant virus-free tissue culture and propagation technologies are used to improve planting materials at the source.

This approach aims to reduce pest and disease pressure while supporting an ecological cultivation model that minimizes the use of pesticides and chemical fertilizers, demonstrating how biotechnology can be translated into applications beyond traditional life science research.

Agricultural facility

4. Core Leadership Team and Industry Recognition

The cover-story subject, Yin Chu, is the Founder and General Manager of Wuhan MiaoLing Bio Technology Co., Ltd. He graduated from Wuhan Institute of Technology with a degree in Pharmaceutical Engineering and started his own business in Optics Valley in June 2014.

With more than a decade of experience in gene vector R&D and commercialization, Yin Chu has led the team in obtaining more than 40 patents, utility model patents, and software copyrights.

Technical team

Supported by its strong technical foundation, MiaoLingBio has received a range of qualifications and industry recognitions, including National High-Tech Enterprise, Wuhan Five-Star High-Tech Enterprise, Wuhan University Student Training Base, Technology-Based SME, and Hubei Innovative SME designations.

In May 2026, the company successfully passed ISO 9001 Quality Management System certification, further strengthening its standardized quality management capabilities.

MiaoLingBio has a technical team in which employees with master's and doctoral degrees account for more than 50% of R&D personnel. Its core technical specialists have extensive industry experience and established expertise in vector design, viral packaging, automated production processes, and business operations management. The team continues to improve its products, technologies, and service systems to better meet evolving research needs.

5. Vision for Future Development

According to the feature, MiaoLingBio has consistently centered its development strategy on standardization, efficiency, and cost-effectiveness. Building on its 100,000-plus in-stock plasmid library, the company continues to upgrade its automated production equipment and optimize its vector and purification technologies.

Looking ahead, MiaoLingBio plans to further expand its in-stock plasmid production capacity and develop a more comprehensive one-stop service platform covering custom vector construction, viral packaging, and stable cell line development.

The company will continue providing reliable, high-quality upstream research tools for gene function studies, cellular model development, and gene therapy drug R&D, helping researchers accelerate their projects and contributing to the continued growth of the biopharmaceutical industry in Optics Valley and beyond.